Not a good buy right now: price is in a clear downtrend (bearish MA stack and worsening MACD), and the stock is trading below a key support zone.
Oversold RSI (RSI_6 ~17.6) can trigger short bounces, but without a confirmed reversal signal (and no proprietary buy signal), downside risk still dominates for an impatient entry.
News flow is positive (FDA clearance/feature approval), but price action is not confirming it yet.
Options positioning looks bullish (low put/call), but overall option activity is light vs normal, reducing confidence that traders are pressing a strong upside bet today.
Hedge funds/insiders: neutral; no reinforcing buying pressure from these cohorts.
Momentum: MACD histogram is negative (-0.0656) and negatively expanding, suggesting selling pressure is increasing, not fading.
Oversold: RSI_6 at ~17.6 indicates extreme oversold conditions—possible reflex bounce risk for shorts, but not a confirmed trend reversal.
Levels: Current price 2.345 is below S1 (2.398), which is a bearish break; next downside reference is S2 (2.149). Upside resistance starts near Pivot (2.801) then R1 (3.204).
Short-term pattern odds (provided): weak near-term bias (-1.69% next week) with a more positive 1-month tilt (+3.92%), implying any upside is more likely to be choppy and delayed rather than immediate.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Bullish skew—open interest put/call 0.28 and volume put/call 0.35 indicate more calls than puts.
Activity: Today’s option volume (401) is only ~35.64% of the 30-day average, so the bullish skew is not backed by heavy participation.
Volatility pricing: 30D IV ~94.16 vs historical vol ~62.27; IV percentile ~76.49 indicates options are relatively expensive and the market is pricing elevated uncertainty.
Net take: Options lean bullish, but the low relative volume and very high IV make this a weaker “confidence” signal for an immediate buy.
Technical Summary
Sell
9
Buy
4
Positive Catalysts
FDA-related catalyst: Nano-X digital X-ray systems received FDA approval/510(k) clearance for cloud-enabled TAP2D image enhancement (Feb 3), improving workflow/diagnostic efficiency narrative.
If the stock reclaims the Pivot (~2.801), it could trigger a technical mean-reversion move toward ~3.20 (R1).
Neutral/Negative Catalysts
with bearish MA structure and worsening MACD increases probability of continuation down toward ~2.15 (S2).
Financial Performance
Latest provided quarter: 2025/Q3.
Revenue: 3.447M, +13.72% YoY (growth, but from a very small base).
Profitability: Net income -13.684M (still deeply negative); EPS -0.21, down -8.70% YoY.
Overall: top-line improving modestly, but losses and negative gross margin remain a major headwind to a durable rerating.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so a verified recent trend in Wall Street ratings cannot be stated.
Wall Street-style pros (based on provided info): FDA clearances can strengthen product credibility and commercialization narrative.
Wall Street-style cons (based on provided info): persistent losses, negative gross margin, and weak technical trend likely keep risk perception high until execution improves.
Wall Street analysts forecast NNOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNOX is 7 USD with a low forecast of 7 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast NNOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNOX is 7 USD with a low forecast of 7 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.280
Low
7
Averages
7
High
7
Current: 2.280
Low
7
Averages
7
High
7
Alliance Global Partners
Buy
downgrade
$9 -> $7
AI Analysis
2025-05-22
Reason
Alliance Global Partners
Price Target
$9 -> $7
AI Analysis
2025-05-22
downgrade
Buy
Reason
Alliance Global Partners lowered the firm's price target on Nano-X Imaging to $7 from $9 and keeps a Buy rating on the shares. The firm cites the company's Q1 revenue missing forecasts, suggesting a challenging macro environment, the analyst tells investors in a research note.
